Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients

AIDS

Volumn 12, Issue 17, 1998, Pages

  Hengge, Ulrich R ^a   Goos, Manfred ^a   Esser, Stefan ^a   Exner, Vanessa ^a   Dötterer, Heidi ^a   Wiehler, Heidi ^a   Borchard, Carsten ^a   Müller, Karsten ^a   Beckmann, Alexandra ^a   Eppner, Marie Therese ^a   Berger, Annemarie ^b   Fiedler, Melanie ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Dermatology; HIV load; Immunotherapy; Interleukin 2; Natural killer cells; Recall antigen test

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2; LAMIVUDINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SAQUINAVIR; ZIDOVUDINE;

ADULT; ADVERSE DRUG REACTION; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DEPRESSION; DIARRHEA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTRITIS; HEADACHE; HERPES; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTIOUS COMPLICATION; INJECTION PAIN; KAPOSI SARCOMA; LYMPHADENOPATHY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MYALGIA; NAUSEA; NOSE CONGESTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SUBCUTANEOUS DRUG ADMINISTRATION; SWEATING; TACHYCARDIA; THRUSH; VOMITING;

EID: 7844229880     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199817000-00003     Document Type: Article

References (36)

1. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280:78-86.
2. Smith KA: Interleukin-2: inception, impact, and implications. Science 1988, 240:1169-1176.
3. Kinter A, Fauci AS: Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement. Immunol Res 1996, 15:1-15.
4. Ullum H, Gotzsche PC, Vivtor I, Dickmeiss E, Skinhoj P, Pedersen BK: Defective natural immunity: an early manifestation of human immunodeficiency virus infection. J Exp Med 1995, 182:789-799.
5. Zerhouni B, Sanhadji K, Kehrli L, Livrozet JM, Touraine JL: Interleukin (IL)-2 deficiency aggravates the defect of natural killer cell activity in AIDS-patients. Thymus 1997, 24:147-156.
6. Thèze J, Alzari PM, Bertoglio J: Interleukin-2 and its receptors: recent advances and new immunological functions. Immunology Today 1996, 17:481-486.
7. Rook AH, Masur H, Lane HC, et al.: Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983, 72:398-403.
8. Lifson JD, Benike CJ, Mark DF, Koths K, Engleman EG: Human recombinant interleukin-2 partly reconstitutes deficient in vitro immune responses of lymphocytes from patients with AIDS. Lancet 1984, 1:698-702.
9. Lin SJ, Roberts RL, Ank BJ, Nguyen QH, Thomas EK, Stiehm ER: Human immunodeficiency virus (HIV) type-1 GP120-specific cell-mediated cytoxicity (CMC) and natural killer (NK) activity in HIV-infected (HIV+) subjects: enhancement with interleukin-2 (IL-2), IL-12, and IL-15. Clin Immunol Immunopathol 1997, 82:163-173.
10. Kovacs JA, Baseler M, Dewar RJ, et al.: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995, 332:567-575.
11. Kovacs JA, Vogel S, Albert JM, et al.: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996, 335:1350-1356.
12. Schwartz DH, Skowron G, Merigan TC: Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquired Immune Def Syn 1991, 4:11-23.
13. McMahon DK, Armstrong JA, Huang XL, et al.: A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV-disease while on zidovudine. AIDS 1994, 8:59-66.
14. Jacobson EL, Pilato F, Smith KA: Rational interleukin-2 therapy for HIV-positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci 1996, 93:10405-10410.
15. Davey RT Jr., Chaitt DG, Piscitelli SC, et al.: Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997, 175:781-789.
16. Tschachler E, Bergstresser PR, Stingl G: HIV-related skin diseases. Lancet 1996, 348:659-663.
17. Uthayakumar S, Nandwani R, Drinkwater T, Nayagam AT, Darley CR: The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression. Br J Dermatol 1997, 137:595-598.
18. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337: 734-739.
19. Gerdes J, Lemke H, Baisch H, et al.: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133:1710-1715.
20. Pachl C, Todd JA, Kern DG, et al.: Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquired Immune Def Syn 1995, 8:446-454.
21. Hengge UR, Chan EF, Foster RA, Walker PS, Vogel JC: Cytokine gene expression in epidermis with biological effects following injection of naked DNA. Nature Genet 1995, 10:161-166.
22. Harris M, Patenaude P, Cooperberg P, et al.: Correlation of virus load in plasma and lymph node tissue in human immunodeficiency virus infection. J Infect Dis 1997, 176:1388-1392.
23. Dailey P, Wilber J, Urdea M: HIV load in lymphoid tissues using branched DNA (bDNA) signal amplification Tenth International Conference on AIDS/International Conference on STD. Yokohama, August, 1994 Tokyo: Japanese Foundation for AIDS Prevention, 1994:2. [abstract PA0200].
24. Hertogs K, de Bethune MP, Miller V, et al.: A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
25. Karlsson A, Moberg L, Brarr G, et al.: An eleven year follow-up of delayed-type hypersensitivity testing for the identification of HIV-1 infected patients at increased risk of developing AIDS. Scand J Infect Dis 1996, 28:125-130.
26. Wu H, Rubin HR, Mathews WC, et al.: A health status questionnaire using 30 items from the medical outcomes study. Preliminary validation in persons with early HIV infection. Med Care 1991, 29:786-798.
27. Siegel JP, Puri RK: Interleukin-2 toxicity. J Clin Oncol 1991, 9:694-704.
28. Gaspari A, Lotze MT, Rosenberg SA, Stern JB, Katz SI: Dermatologic changes associated with interleukin-2 administration. JAMA 1987, 258:1624-1629.
29. + T cell activation. Clin Immunol Immunopathol 1993, 67:185-191.
30. Vanham G, Kestens L, Vingerhoets J, et al.: The interleukin-2 receptor subunit expression and function on peripheral blood lymphocytes from HIV-infected and control persons. Clin Immunol Immunopathul 1994, 71:60-68.
31. Caliguiri MA, Murray C, Robertson MJ, et al.: Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin-2. J Clin Invest 1993, 91:123-132.
32. Lempicki RA, Parlick MV, Donoghue ET, Lowry RP, Lane HC: IL-2 relieves spontaneous G1 arrest in CD8+ T-cells from HIV+ individuals. 4th National Conference on HIV/AIDS. Washington D.C. January 1996, [abstract Tu-A 382].
33. Tissot O, Viard JP, Rabian C, et al.: No evidence for proliferation in the blood CD4+ T-cell pool during HIV-1 infection and triple combination therapy. AIDS 1998, 12:879-884.
34. Clark AGB, Holodniy M, Schwartz DH, Katzenstein A, Merigan TC: Decrease in HIV-provirus in peripheral blood mononuclear cells during zidovudine and human IL-2 administration. J Acquired Immune Def Syn 1992, 5:52-59.
35. Connors M, Kovacs JA, Kreval S, et al.: HIV infection induces changes in CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Medicine 1997, 3:533-540.
36. Gorochov G, Neumann AU, Kereveur A, et al.: Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiretroviral therapy. Nat Medicine 1998, 4:215-221.